Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia

Drugs
R C HeelG S Avery

Abstract

Colestipol is an anion exchange resin with bile acid sequestering properties resembling those of cholestyramine, another lipid-lowering binding resin. In daily doses of 15 to 30g colestipol reduces total plasma cholesterol concentrations (primarily low density lipoprotein cholesterol) by about 15 to 30%, but plasma triglyceride concentrations may be unchanged or in some patients increased. Thus, like cholestyramine, colestipol is of benefit in patients with primary hypercholesterolaemia without associated hypertriglyceridaemia (type IIa hyperlipoproteinaemia). Colestipol is odourless and tasteless, and is said by some to be more readily tolerated by patients than cholestyramine, leading to improved compliance, but such data has not been documented in most studies. Side effects of colestipol treatment are primarily gastrointestinal in nature since the drug is essentially unabsorbed. As with cholestyramine, colestipol may bind with other concomitantly administered drugs reducing their absorption or enterohepatic recirculation; dosage intervals of other concurrent medications should be adjusted to minimise the potential for such an interaction.

Citations

May 4, 2005·Cardiovascular Drug Reviews·Karen L Steinmetz, Kristine S Schonder
May 4, 2011·World Journal of Diabetes·Kohzo TakebayashiToshihiko Inukai
Feb 20, 2015·European Heart Journal·Erik S StroesUNKNOWN European Atherosclerosis Society Consensus Panel
Jan 1, 1988·Acta paediatrica Scandinavica·P SanjurjoI Cabeza
Jun 15, 1983·Klinische Wochenschrift·O Leiss, K von Bergmann
Mar 1, 1993·Medicinal Research Reviews·P A McCarthy
Jun 3, 2016·Expert Opinion on Pharmacotherapy·Jaideep PatelMaciej Banach
Jan 1, 1987·Medical Toxicology·L C Knodel, R L Talbert
Nov 1, 1984·Postgraduate Medicine·T R Glatter
Jul 1, 1984·Progress in Cardiovascular Diseases·W V BrownH N Ginsberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.